Sirolimus-based regimen promotes inhibitory costimulatory signal of HVEM/BTLA/CD160/LIGHT pathway in allo-renal recipients
Sirolimus-based regimen promotes inhibitory costimulatory signal of HVEM/BTLA/CD160/LIGHT pathway in allo-renal recipients
复制标题
基于西罗莫司的方案促进异体肾受体 HVEM/BTLA/CD160/LIGHT 通路的抑制性共刺激信号
DOI：
10.1016/j.trim.2012.11.005
复制
发表时间：
2013-01-01
影响因子：
1.5
通讯作者：
Wang, Lanlan
中科院分区：
文献类型：
--
作者：
Bai, Yangjuan;Shi, Yunying;Wang, Lanlan
HVEM/BTLA/CD160/LIGHT通路是一个非常特殊的共刺激分子系统，它可通过激活炎症信号和抑制信号来调节T细胞免疫反应。西罗莫司对肾移植受者HVEM共刺激系统的调节作用尚未见报道。在本研究中，我们通过流式细胞术分析了循环T细胞亚群上HVEM、BTLA、CD160和LIGHT的表达情况，以及CD4 +调节性T细胞（Tregs）上HVEM的表达情况，同时利用自动分析仪检测了西罗莫司的给药前浓度。研究纳入了接受西罗莫司免疫抑制方案的肾移植受者和健康志愿者。接受西罗莫司方案的肾移植受者T细胞上BTLA和CD160的表达显著增加，而T细胞上LIGHT的表达显著降低（p （此处p后似乎缺少具体内容 ）
HVEM/BTLA/CD160/LIGHT pathway is a very special costimulatory molecule system which can regulate T-cell immune responses by activating both inflammatory and inhibitory signalings. The regulatory effect of Sirolimus on HVME costimulatory system in allo-renal recipients has not been reported. In this study, we analyzed the expression of HVEM, BTLA, CD160 and LIGHT on circulating T cell subgroups and the expression of HVEM on CD4 + Tregs by flow cytometry and also the pre-dose concentration of Sirolimus by automatic analyzer. Both the allo-renal recipients receiving Sirolimus immunosuppressive regimen and health volunteers were included. The expression of both BTLA and CD160 on T cells increased significantly while the expression of LIGHT on T cells decreased significantly in allo-renal recipients receiving Sirolimus regimen (p